Summary
This 8-K filing by Boston Scientific Corporation (BSX) on June 29, 2005, announces the resolution of a significant legal matter. The company has entered into a civil settlement with the U.S. Department of Justice for $74 million to conclude an investigation dating back to 1998 concerning the recall of its NIR ON® Ranger™ with Sox™ coronary stent delivery system and its relationship with vendor Medinol. The settlement, finalized on June 24, 2005, brings closure to a federal grand jury investigation where Boston Scientific and two senior officials were targets. Importantly, the Department of Justice filed a dismissal with prejudice, meaning no charges were brought against the company or any employee, and there is no admission of wrongdoing by Boston Scientific. This resolution removes a significant overhang for investors, allowing the company to focus on its core operations.
Key Highlights
- 1Boston Scientific has reached a $74 million civil settlement with the U.S. Department of Justice to resolve an investigation initiated in 1998.
- 2The investigation primarily concerned the recall of the NIR ON® Ranger™ with Sox™ coronary stent delivery system and relationships with vendor Medinol.
- 3The settlement brings closure to a federal grand jury investigation where the company and two senior officials were targets.
- 4The Department of Justice filed a dismissal with prejudice, indicating no charges were brought against Boston Scientific or any employees.
- 5The settlement includes no admission of wrongdoing by Boston Scientific or its employees.
- 6This filing represents a significant legal resolution, removing a long-standing uncertainty for investors.